Aurobindo Pharma Secures USFDA Final Approval for Generic Fycompa Tablets
Aurobindo Pharma Ltd 路 Press Release 路 03 Oct 2026, 10:39 pm
Aurobindo Pharma Secures USFDA Final Approval for Generic Fycompa Tablets Aurobindo Pharma received USFDA final approval on 3rd Oct'26 to manufacture and market Perampanel Tablets (2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg), bioequivalent to Catalyst Pharmaceuticals' Fycompa. Indicated for epilepsy seizures, the product addresses a US$ 67 million market (IQVIA MAT Aug'26). Manufacturing will occur at wholly owned subsidiary APL Healthcare's Unit-IV, with a planned launch in Q3FY27. This brings Aurobindo's cumulative USFDA tally to 599 ANDA approvals, comprising 574 final and 25 tentative approvals.
Original exchange filing (PDF)
More announcements from Aurobindo Pharma Ltd
- Intimation of classification of US FDA inspection at Lannet Company LLC, a wholly owned subsidiary of Aurobindo Pharma USA Inc., a wholly owned subsidiary of the Company. 路 12 Nov 2026
- Submission of Earning Call Transcript for Q2FY27. 路 11 Nov 2026
- Unit-2 of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company received Establishment Inspection Report from US FDA with classification as "Voluntary Action Indicated". 路 11 Nov 2026
- Intimation of investors / analysts meet to be held on 17.11.2026. 路 09 Nov 2026
- Intimation of investor / analysts meet to be held on 16.09.2026. 路 09 Nov 2026
- Submission of Financial results for the Quarter and Half year ended September 30, 2026. 路 05 Nov 2026
- Reappointment of Mr. M. R. Kumar as Independent Director of the Company for second term with effect from April 1, 2027. 路 05 Nov 2026
- Transfer of ownership of Auro Pharma LLC, Russia from Auroactive Pharma Private Limited to Auropharm Overseas Limited, Wholly Owned subsidiaries of the Company. 路 05 Nov 2026
